Despite the significant advances achieved in the treatment of hematological malignancies, such as the use of CD19 CARs in leukemia, the use of CAR T cell therapy for solid tumors has not attained comparable levels of success [35]. The gene discussed is CD19; the disease is hematologic disorder.